Wellspring Financial Advisors LLC Acquires 4,612 Shares of Merck & Co., Inc. $MRK

Wellspring Financial Advisors LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 30.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,780 shares of the company’s stock after purchasing an additional 4,612 shares during the quarter. Wellspring Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at $25,000. United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. during the third quarter valued at $31,000. High Note Wealth LLC increased its position in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the last quarter. Tucker Asset Management LLC purchased a new stake in Merck & Co., Inc. during the fourth quarter valued at $34,000. Finally, Wealth Watch Advisors INC purchased a new stake in Merck & Co., Inc. during the third quarter valued at $34,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Wells Fargo reiterated its Buy rating on Merck, adding to the recent analyst support around the stock and reinforcing confidence in the company’s long-term outlook. Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
• Positive Sentiment: Merck and Gilead reported positive Phase III HIV data for their once-weekly islatravir/lenacapavir regimen, which could expand Merck’s infectious-disease franchise if regulatory filings proceed as planned. Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Positive Sentiment: Merck said it is expanding its EU digital traceability efforts and exploring options to help address the emerging Bundibugyo Ebola outbreak, highlighting new commercial and public-health initiatives. Merck Expands EU Traceability Push And Targets Bundibugyo Ebola Response
• Positive Sentiment: Technical coverage noted that MRK has moved back above its 50-day moving average while staying above its 200-day trendline, with Keytruda growth and pipeline progress supporting the investment case. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Neutral Sentiment: Merck was highlighted in research roundups and conference coverage, but these items were mainly recap-oriented and did not introduce a major new catalyst. Top Research Reports for Merck, Southern Company & Lumentum Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Merck and Gilead also ended a Phase III non-small-cell lung cancer study after it failed to meet its efficacy bar, which may temper enthusiasm around some of Merck’s oncology pipeline efforts. Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Friday, February 13th. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Barclays assumed coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $118.99 on Thursday. The firm has a market cap of $293.89 billion, a price-to-earnings ratio of 33.52, a price-to-earnings-growth ratio of 2.69 and a beta of 0.21. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The business has a 50-day moving average price of $116.58 and a 200-day moving average price of $113.02. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.